정규장
Log in Sign up
🏛️
거래 정지 중인 종목 2026-06-22 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.
PRTC
PRTC
Protech Inc
6월 8일 4:00 PM ET (한국 6/9 05:00)
$17.42
+0.00 +0.00%

프로텍(PRTC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$424M
스몰캡
P/E
-
배당수익률
없음
52주 위치
54%
저점 +20% · 고점 -13%
애널리스트
-
D
Fundamental health
vs. Biotechnology 소형주· based on 1 axes
수익성
데이터 부족
성장
데이터 부족
밸류에이션
Top 61%
재무 안정
데이터 부족
Index -P/E -EPS (ttm) -4.6Insider Own -Shs Outstand 24.3MPerf Week -
Market Cap 0.42BForward P/E -EPS next Y -Insider Trans -Shs Float -Perf Month 4.37%
Enterprise Value -PEG -EPS next Q -Inst Own 0.58%Short Float -Perf Quarter 1.34%
Income -P/S 91.01EPS this Y -Inst Trans -Short Ratio 0.9Perf Half Y 3.75%
Sales 0.00BP/B 1.35EPS next 5Y -ROA -Short Interest 0.01MPerf YTD 4.69%
Book/sh 12.91P/C -EPS past 3/5Y -ROE -52W High -12.55% ($19.92)Perf Year -0.03%
Cash/sh -P/FCF -Sales past 3/5Y -ROIC -52W Low 20.14% ($14.50)Perf 3Y -30.65%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -312.58%Gross Margin -Volatility(W/M) 3.75% 4.31%Perf 5Y -66.88%
Dividend TTM -EV/Sales -Sales Y/Y TTM -3.44%Oper. Margin -ATR (14) 0.79Perf 10Y -
Dividend Ex-Date -Quick Ratio -EPS Q/Q -Profit Margin -RSI (14) 51.77Recom -
Dividend Gr. 3/5Y -Current Ratio -Sales Q/Q -38.2%SMA20 0.51% ($17.33)Beta 1.15Target Price -
Payout -Debt/Eq -Earnings 2026/4/29SMA50 3.4% ($16.85)Rel Volume 0Prev Close $17.42
Employees -LT Debt/Eq -EPS/Sales Surpr. 6.86% -93.19%SMA200 0.45% ($17.34)Avg Volume(3M) 0.01MPrice $17.42
IPO 2020/11/16Option/Short No/NoTrades 0Volume -Change -
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Protech Inc (PRTC) Investment Analysis

What kind of company is Protech Inc?

프로텍(PRTC)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 Prothena (PRTC) is a clinical-stage biopharmaceutical company that discovers and develops new drug candidates based on its proprietary platform and a founded entity model. It maintains a pipeline in the areas of pulmonary fibrosis, oncology, and neuropsychiatry, and is characterized by a structure in which its core assets are spun off into independent subsidiaries to drive value growth.

Learn more about Protech Inc →
Market Cap
$0.4B
Approx. KRW 0.6 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3339
IPO2020/11/16
Current Price$17.42 ≈ 23,865원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 4월 29일 (수) · 장 시작 전 EPS +6.9% 매출 -93.2%

Is it profitable?

Financial metrics unavailable

Profitability and financial-health indicators have not yet been collected.

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 1 of the last 1 quarters
1
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+6.9%
평균 서프라이즈
2026.04.29
상회
+6.9%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-38.2%
매우 부진
My positionBottom 5%
Low range Average High range
미분류 소형주 Median 6.3% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -135%p below the market
PRTC -66.9% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-135.2%p
Significantly behind the market
vs Health Care (XLV)
-91.4%p
Significantly behind the sector average
1-year basis
vs S&P 500
-16.0%p
behind the market
vs Health Care (XLV)
-19.8%p
behind the sector average
Rank among peers
5-year return Lower-Mid (lower 43%) Based on 123 peers
1-year return Bottom 25% Based on 154 peers
Current position within 52-week range
Low (-20.1%p) High (-12.6%p)
Current price is 20.1% above the 52-week low and 12.6% below the 52-week high
Recent risk (last 95 trading days)
Max drawdown
-24.1%
Annualized volatility
38.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 102-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡
Current diagnosis · 2026-06-05
Squeeze — volatility contraction, breakout imminent

Band width narrowed to 5.0%. Big move may be near. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-06-05
Neutral zone — weak trend

MACD 0.056 · Signal 0.064 · Hist -0.008. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-06-05
Bullish zone

RSI 51.8 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 62.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Assets, Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🧾 Vs. Sales Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.35x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 소형주 median 3.34x · Top 1% — relatively cheap within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
91.01x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 소형주 median 14.61x · Bottom 22% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership is broadly stable
👥 Holdings composition
🏦 Institutions 0.6%
Retail-led
Healthcare 소형주 Median 65.6%
👤 Retail investors (estimated) 99.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
-
Short interest days to cover
0.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 24.3M주
Float (tradable shares) -
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 0 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PRTC PRTC This Stock
$424.0M- 1.4 - - +0.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 프로텍(PRTC)?

프로텍(PRTC) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PRTC?

The market cap of PRTC is approximately $424M, ranking 3,339 within its sector.

What is the 52-week high and low for PRTC?

PRTC has recorded a 52-week high of $19.92 and a low of $14.50.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.